Treatment of Androgenetic Alopecia in Males

Launched by LEXINGTON INTERNATIONAL, LLC · Jul 27, 2009

Keywords

ClinConnect Summary

This is randomized, double-blind, control device clinical study across 2 sites, evaluating changes in terminal hair-count in the evaluation zone having evidence of androgenetic alopecia (miniaturized hair).

The trial will involve 45 male subjects who have been diagnosed with androgenetic alopecia, who are between 25 and 60 years of age, have Fitzpatrick Skin Types I-IV, with classifications of Norwood-Hamilton IIa to V, have active hair loss within the last 12 months.

Subjects will use the device on three nonconcurring days a week as directed per device for 26 weeks treatment duration.

I...

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of androgenetic alopecia
• • Fitzpatrick Skin Types I-IV
• • Norwood-Hamilton IIa to V
• • Active hair loss within last 12 months
• Exclusion Criteria:
• • Photosensitivity to laser light
• • Malignancy in the target area